Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Notified -
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-02-22, 14:20
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-12-17, 19:30
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-05-29, 17:30
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-01-30, 19:32
Anti-Drone Industry Size is Anticipated to Gain $3.8 Bn by
Chicago, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Anti-Drone Industry by Technology (Electronic, Laser, and Kinetic Systems), Application (Detection, Detection...
